Do Inhaled Corticosteroids Reduce All-Cause Mortality Risk in Patients With COPD?



STUDY DESIGN

- Conducted **meta-analysis** of **60** randomized controlled trials which enrolled **103,034** patients
- Compared all-cause mortality in those inhaled therapies with and without inhaled corticosteriods (ICS)
- Pooled results were calculated using Peto ORs



RESULTS

All-cause mortality

- Reduced with inhaled therapy **containing ICSs** (Peto OR 0.90; 0.84-0.97)
- **Triple therapy** had even stronger reduction in all-cause mortality (Peto OR 0.73; 0.59-0.91)
- **Eosinophil counts** of >200/mL were strongest predictor of association

Patients treated with inhaled therapy containing ICSs had reduced all-cause mortality risk. Triple therapy and eosinophil counts of >200/mL were the strongest predictor of reduction.

Chen H, et al. CHEST January 2022 | @journal_CHEST | https://doi.org/10.1016/j.chest.2022.07.015

Copyright © 2022 American College of Chest Physicians